A seasoned and highly successful healthcare executive with over 25 years experience in the pharmaceutical industry, Mark Altmeyer joined Otsuka America Pharmaceutical, Inc. (OAPI) in January 2009 as President and CEO. Committed to taking OAPI to the next level of growth and development, Mr. Altmeyer has strategically re-aligned its leadership by bringing in a team of accomplished industry leaders to complement the existing corps of talented executives. In addition to immediately strengthening OAPI’s relationships with its development and promotion partners, as president he oversaw the launch of Samsca©, an oral hyponatremia medication, positioning the company to operate in a new and exciting healthcare sphere. He has also embarked on a company-wide initiative to enhance the current sales and marketing organizations with additional best-in-class talent, establishing OAPI as an independent marquis healthcare brand throughout the U.S. Altmeyer earned his well-deserved reputation as a drug commercialization strategist and leader prior to coming to Otsuka, with over 16 years in sales and marketing with BMS, rising from Sales Representative to SVP, Global Commercialization. During those years, he delivered on premier brands including Pravachol, Glucophage, and ABILIFY. Extending his successes beyond the U.S. market, Mr. Altmeyer worked internationally as the general manager of BMSs operations in Turkey, leading to his appointment as SVP, Global Commercialization. In that position, he was responsible for the global marketing of all neuroscience and oncology assets – the therapeutic areas on which Otsuka is focusing, and which will help drive Otsuka’s future growth. Prior to joining BMS in 1992, Altmeyer devoted his efforts to marketing and development for Cetus Corporation, both as a product manager in oncology and a business development manager. He started his career with Bristol Labs, a division of Bristol-Myers, as a marketing associate and group product analyst. Mr. Altmeyer earned his BA from Middlebury College in Vermont, and his MBA from Harvard Business School.
Matthew Gantz joined BTG plc in February 2009 as EVP US with responsibility for BTG’s commercial operations in the US. Prior to BTG, Matthew was Founder and CEO of Acureon Pharmaceuticals, a specialty pharmaceutical company focused in the hospital areas of infectious diseases, transplant and ICU. Prior to Acureon, he was the President and CEO of Hydrabiosciences Inc, a privately held biotechnology company developing novel, ion channel medicines in the pain and cardiovascular area. From 2000 to 2003, Matthew was the VP Europe for Chiron’s Biopharmaceutical Division where he was directly responsible for $100+ million Infection Disease and Oncology business. From 1996 to 2000 he was the GM for PathoGenesis Europe before the company was acquired by Chiron. Prior to Chiron/PathoGenesis, Matthew held a variety of US sales and marketing roles at Abbott Laboratories Diagnostics Division. Matthew served as an infantry officer in the US Marine Corps, earned his MBA from Harvard and his undergraduate degree from Princeton University.
Dr Bill Trombetta is Professor of Pharmaceutical Marketing on the Faculty of the Erivan K Haub School of Business. He is well known in the biopharm industry as the author of a much-quoted feature for Pharmaceutical Executive magazine, the Annual Industry Audit, which ranks the industry's true top performing companies using weighted metrics, with the company receiving the highest number of points overall designated as the Company of the Year. This year’s Sept 2009 edition marked the 8th annual publication of Dr. Trombetta’s Industry Audit. Dr. Trombetta received his PhD in Marketing from the Ohio State University. He is also an attorney licensed in New Jersey and New York specializing in healthcare/antitrust law.
As a 30+ year seasoned veteran of the health care industry, Nancy J. Wysenski, most recently Chief Operating Officer of Endo Pharmaceuticals, has been sought out by a variety of health care firms to help guide their respective organizations. Prior leadership positions have included President and founding member of EMD Pharmaceuticals, Inc., Senior Vice President of Operations at NetGenic, and Vice President of Field Sales at AstraMerck. During her AstraMerck days, Professor Frank Cespedes of the Harvard Business School wrote a case study on the firm given the unique operating model that Ms. Wysenski and her colleagues had created. Prior to joining Astra Merck in 1992, she held a number of positions at Merck Human Health. Ms. Wysenski is a graduate of Kent State University with a B.Sc and holds an M.B.A. from Baldwin Wallace College.
Event Details
Our discussion will be held on Thursday Nov 12, at the Haub School of Business’ Mandeville Hall, Room 313, located on the campus of St Joseph’s University at the corner of City Avenue and N 54th Street in Philadelphia, PA (directions available at www.sju.edu/about/campusmap/index.html). Parking is available at the parking lot on N 54th Street outside of Mandeville Hall, as well as at the parking garage across the street.
Networking and sandwich buffet and refreshments will be from 6:00 PM to 6:45 PM with our program beginning promptly at 6:45 PM. Joining us at this event will be local alumni from other top business schools and undergraduate institutions.
The cost of this event is $20 for HBSCP Basic and PBC members and their guests. It is free to Patrons and Sponsor members as well as one Sponsor's guest. Non HBS alumni are welcome to attend for $20 as well. Online sign-up is encouraged on the HBSCP website at www.hbsphilly.com.
If you have questions or would like more information, please contact:
Michael Wong at mwong@cobbscreekhealthcare.com; Jun Huangpu at jhuangpu@cobbscreekhealthcare.com; or Harry Atkins at hatkins@mba1992.hbs.edu
